Atrial Fibrillation and By-pass Surgery

Pharmacologic Prophylaxis for Atrial Fibrillation Following Coronary By-Pass Surgery

Status

UNKNOWN

Phases

Early Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01955759

Enrollment

260

Registered

2013-10-07

Start date

2013-12-31

Completion date

2015-02-28

Last updated

2013-12-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients With Coronary Artery Disease Scheduled for by Pass Surgery

Brief summary

The aim of the study is to evaluate whether combined therapy with beta-blocker, amiodarone and statine is better than beta-blocker alone for the prevention of atrial fibrillation after coronary by-pass surgery.

Interventions

DRUGAmiodarone tab 200 mg x 3

starting 7 days before coronary by-pass surgery per os 200 mg. x 3 tab, followed by 200 mg x 2 tab per os starting on the second postoperative day untill discharge

DRUGrosuvastatin 20 mg tab x1

starting 7 days before coronary by-pass surgery

DRUGbeta blockers Bisoprolol in adjusted dose

starting 7 days befoe coronary by-pass surgery

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Masking

TRIPLE (Subject, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* significant coronary disease, sinus rhythm

Exclusion criteria

* valvular disease, former by-pass surgery

Design outcomes

Primary

Measure	Time frame	Description
atrial fibrillation	10 days on average during hospital stay after coronary by-pass surgery	outcome will be number of patients free from atrial fibrillation.

Countries

Bosnia and Herzegovina

Contacts

Primary ContactEnes Osmanovic, Master's degree

osmanovic@bhsrce.ba+387 66 725 744

Backup ContactGoran Imamovic

goran.imamovic@fmc-ag.com

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026